Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YH42946 in Advanced Solid Tumors with HER2 Aberration and EGFR Exon 20 Insertion
NCT06616766Phase 2Recruiting
- Sponsor
- Yuhan
- Start
- Oct 2024
- Primary completion
- Mar 2028
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of YH42946 in solid tumor and non-small cell lung cancer (NSCLC), sponsored by Yuhan. Primary endpoints: Treatment Emergent Adverse Events at 21 days and Objective Response Rate at 12 months. Started Oct 2024; status: recruiting.
02
Drugs
YH42946
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06616766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06616766.